ES2318856T4 - Composiciones farmaceuticas para la prevencion y el tratamiento de trastornos del sistema nervioso central. - Google Patents

Composiciones farmaceuticas para la prevencion y el tratamiento de trastornos del sistema nervioso central. Download PDF

Info

Publication number
ES2318856T4
ES2318856T4 ES97921232T ES97921232T ES2318856T4 ES 2318856 T4 ES2318856 T4 ES 2318856T4 ES 97921232 T ES97921232 T ES 97921232T ES 97921232 T ES97921232 T ES 97921232T ES 2318856 T4 ES2318856 T4 ES 2318856T4
Authority
ES
Spain
Prior art keywords
methyl
amine
compound
pyridinyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97921232T
Other languages
English (en)
Spanish (es)
Other versions
ES2318856T3 (es
Inventor
William Scott Caldwell
Gary Maurice Dull
Grayland Page Dobson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gyre Therapeutics Inc
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24532629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2318856(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of ES2318856T3 publication Critical patent/ES2318856T3/es
Application granted granted Critical
Publication of ES2318856T4 publication Critical patent/ES2318856T4/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES97921232T 1996-04-23 1997-04-16 Composiciones farmaceuticas para la prevencion y el tratamiento de trastornos del sistema nervioso central. Expired - Lifetime ES2318856T4 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63176196A 1996-04-23 1996-04-23
US631761 1996-04-23

Publications (2)

Publication Number Publication Date
ES2318856T3 ES2318856T3 (es) 2009-05-01
ES2318856T4 true ES2318856T4 (es) 2010-03-03

Family

ID=24532629

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97921232T Expired - Lifetime ES2318856T4 (es) 1996-04-23 1997-04-16 Composiciones farmaceuticas para la prevencion y el tratamiento de trastornos del sistema nervioso central.

Country Status (12)

Country Link
US (2) US6603011B1 (enExample)
EP (2) EP1997806A1 (enExample)
JP (2) JP4357001B2 (enExample)
AT (1) ATE416164T1 (enExample)
AU (1) AU727976B2 (enExample)
BR (1) BR9708815B1 (enExample)
CA (1) CA2252515C (enExample)
DE (1) DE69739142D1 (enExample)
DK (1) DK0900200T5 (enExample)
ES (1) ES2318856T4 (enExample)
PT (1) PT900200E (enExample)
WO (1) WO1997040011A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166048A (en) 1999-04-20 2000-12-26 Targacept, Inc. Pharmaceutical compositions for inhibition of cytokine production and secretion
US20020052497A1 (en) 2000-03-09 2002-05-02 Targacept, Inc. Compounds capable of activating cholinergic receptors
US6979695B2 (en) 1996-04-23 2005-12-27 Targacept, Inc. Compounds capable of activating cholinergic receptors
MXPA00009619A (es) 1998-04-02 2006-03-09 Targacept Inc Composiciones farmaceuticas y metodos de uso.
US20050131034A1 (en) * 1998-06-16 2005-06-16 Caldwell William S. Compounds capable of activating cholinergic receptors
CA2709735A1 (en) * 1998-06-16 1999-12-23 Targacept, Inc. Aryl substituted olefinic amines and their use as cholinergic receptors agonists
US6232316B1 (en) 1998-06-16 2001-05-15 Targacept, Inc. Methods for treatment of CNS disorders
US7790757B2 (en) 1998-06-16 2010-09-07 Targacept, Inc. Compounds capable of activating cholinergic receptors
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
AU2005201609B2 (en) * 1999-04-20 2007-10-18 Targacept, Inc Pharmaceutical compositions for inhibition of cytokine production and secretion
US20010031771A1 (en) 1999-05-24 2001-10-18 Gary Maurice Dull Pharmaceutical compositions and methods for use
EP1185514A1 (en) * 1999-06-07 2002-03-13 Targacept, Inc. Pharmaceutical compositions and methods for use
JP2003505508A (ja) * 1999-07-30 2003-02-12 バーテックス ファーマシューティカルズ インコーポレイテッド 非環式又は環式アミド誘導体
WO2001082978A2 (en) * 2000-05-01 2001-11-08 Targacept, Inc. Imaging of nicotinic acetylcholine receptor subtypes
FR2838436A1 (fr) * 2002-04-16 2003-10-17 Rhodia Chimie Sa Composes amines porteurs d'au moins un allyle et d'un difluoromethyle et procede utile a leur synthese
FR2847578A1 (fr) * 2002-11-21 2004-05-28 Rhodia Chimie Sa Composes amines porteurs d'au moins un allyle et d'un difluoromethyle et procede utile a leur synthese
JP2005523339A (ja) * 2002-04-16 2005-08-04 ロディア・シミ 少なくともアリル及びジフルオロメチルを有するアミノ化化合物及びそれらの合成に使用される方法
ES2330849T3 (es) * 2004-04-02 2009-12-16 Arterial Remodelling Technologies Inc. Ensamblaje de stent basado en polimero.
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
UA88792C2 (ru) * 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
US8017785B2 (en) 2006-05-09 2011-09-13 Astrazeneca Ab Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine
TWI389889B (zh) * 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
CL2007002684A1 (es) * 2006-09-15 2008-06-27 Astrazeneca Ab Targacept Inc Combinacion que comprende un antipsicotico y (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina; composicion farmaceutica que la comprende; kit farmaceutico; y uso para tratar perjuicio cognitivo y/o trastorno psicoticos.
WO2008091588A1 (en) * 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
US20110098312A1 (en) * 2008-05-12 2011-04-28 Targacept ,Inc Methods for preventing the development of retinopathy by the oral administration of nnr ligands
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
CN103180277A (zh) 2010-05-20 2013-06-26 塔格塞普特股份有限公司 制备芳基取代的烯属胺的新方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965074A (en) 1985-03-05 1990-10-23 Ciba-Geigy Corporation Method of treating memory impairment
US4684654A (en) * 1985-08-14 1987-08-04 American Cyanamid Company 3-heteroalkyl-2,4-quinzaolinediones
US4788206A (en) * 1987-07-10 1988-11-29 Hoffmann-La Roche Inc. Pentadieneamides
US4927838A (en) * 1987-07-10 1990-05-22 Hoffman-La Roche Inc. Pyridine compounds which are useful in treating a disease state characterized by an excess of platelet activating factors
US4786646A (en) * 1987-07-10 1988-11-22 Hoffmann-La Roche Inc. Cyclopropylpropenamides
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
US5210076A (en) 1988-09-13 1993-05-11 Berliner David L Methods of treating Parkinson's disease using melanin
US5356906A (en) 1989-10-27 1994-10-18 The Du Pont Merck Pharmaceutical Company (N-phthalimidoalkyl) piperidines useful as treatments for psychosis
DE4102289A1 (de) 1991-01-26 1992-07-30 Bayer Ag Verfahren zur herstellung von (hetero)arylalk(en/in)-ylaminen und neue (hetero)arylkinylamine
ES2153360T3 (es) 1991-05-29 2001-03-01 Abbott Lab Compuestos de isoxazol e de isotiazol que mejoran las funciones de razonamiento.
US5212188A (en) 1992-03-02 1993-05-18 R. J. Reynolds Tabacco Company Method for treatment of neurodegenerative diseases
US5242935A (en) 1992-03-06 1993-09-07 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5227391A (en) 1992-04-10 1993-07-13 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5723477A (en) 1994-11-10 1998-03-03 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
WO1996020600A1 (en) * 1995-01-06 1996-07-11 R.J. Reynolds Tobacco Company Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US5616707A (en) * 1995-01-06 1997-04-01 Crooks; Peter A. Compounds which are useful for prevention and treatment of central nervous system disorders
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds

Also Published As

Publication number Publication date
ES2318856T3 (es) 2009-05-01
AU727976B2 (en) 2001-01-04
CA2252515A1 (en) 1997-10-30
JP2008247903A (ja) 2008-10-16
EP0900200B1 (en) 2008-12-03
DK0900200T5 (da) 2010-01-11
EP1997806A1 (en) 2008-12-03
ATE416164T1 (de) 2008-12-15
US20020032206A1 (en) 2002-03-14
DE69739142D1 (de) 2009-01-15
EP0900200A1 (en) 1999-03-10
DK0900200T3 (da) 2009-03-30
BR9708815B1 (pt) 2009-01-13
AU2733297A (en) 1997-11-12
JP2000509041A (ja) 2000-07-18
US6603011B1 (en) 2003-08-05
CA2252515C (en) 2006-11-07
JP4357001B2 (ja) 2009-11-04
EP0900200B9 (en) 2009-10-21
PT900200E (pt) 2009-02-26
WO1997040011A1 (en) 1997-10-30
BR9708815A (pt) 2000-01-04
US6555684B2 (en) 2003-04-29

Similar Documents

Publication Publication Date Title
ES2318856T4 (es) Composiciones farmaceuticas para la prevencion y el tratamiento de trastornos del sistema nervioso central.
US5616716A (en) (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
US5597919A (en) Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5726316A (en) Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US6274606B1 (en) Methods of treating central nervous system disorders with aryl substituted olefinic amine compounds
ES2228054T3 (es) Aminas olefinicas sustituidas con arilo y su uso como agonistas de receptores colinergicos.
US5824692A (en) Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US5731314A (en) Pharamceutical compositions for prevention and treatment of tourette's syndrome
EP0801527B1 (en) Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US7045538B2 (en) Compounds capable of activating cholinergic receptors
US20040214835A1 (en) Compounds capable of activating cholinergic receptors
EP0973743B1 (en) Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
US6531606B1 (en) Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
US7060826B2 (en) Compounds capable of activating cholinergic receptors
KR100568997B1 (ko) 중추신경계질환의예방및치료를위한약제학적조성물
HK1126213A (en) Pharmaceutical compositions for prevention and treatment of central nervous system disorders
MXPA00012858A (en) Aryl substituted olefinic amines and their use as cholinergic receptors agonists